Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEN301 in Autoimmune Diseases
NCT07527936Phase 1Suspended
- Sponsor
- Renji Hospital
- Start
- Apr 2026
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BEN301 in systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren's syndrome and 1 more (2 arms), sponsored by Renji Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Event up to 2 years. Started Apr 2026; status: suspended.
02
Drugs
BEN301
03
Conditions
systemic sclerosis (SSc)rheumatoid arthritis (RA)Sjögren's syndromeidiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07527936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527936.